BPG is committed to discovery and dissemination of knowledge
Articles in Press
2/13/2026 3:24:58 AM | Browse: 0 | Download: 0
| Category |
Cell Biology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Interpreting the protective role of exogenous nicotinamide adenine dinucleotide in myocardial ischemia/reperfusion injury: Insights into the ROS-NLRP3-pyroptosis axis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Li Jia, Zi-Wei Wang and Guo-Hua Gong |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Guo-Hua Gong, Full Professor, Professor, Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, No. 82 West College Road, Wenzhou 325035, Zhejiang Province, China. guohgong@wmu.edu.cn |
| Key Words |
Nicotinamide adenine dinucleotide; Hypoxia/reoxygenation; Reactive oxygen species; H9c2; Oxidative stress |
| Core Tip |
This commentary highlights recent evidence suggesting that exogenous nicotinamide adenine dinucleotide (NAD⁺) protects against myocardial ischemia/reperfusion injury by interrupting the reactive oxygen species-NLR family pyrin domain containing 3-pyroptosis axis. In addition to simply replenishing metabolic substrates, NAD⁺ acts as a “metabolic-immune” dual regulator, effectively suppressing inflammatory cascades and preventing gasdermin D-mediated cell death. These insights position NAD⁺ not only as an antiaging supplement but also as a promising, broad-spectrum therapeutic strategy for preserving myocardial viability in acute cardiac events. |
| Citation |
Jia L, Wang ZW, Gong GH. Interpreting the protective role of exogenous nicotinamide adenine dinucleotide in myocardial ischemia/reperfusion injury: Insights into the ROS-NLRP3-pyroptosis axis. World J Cardiol 2026; In press |
 |
Received |
|
2025-12-16 01:38 |
 |
Peer-Review Started |
|
2025-12-16 01:39 |
 |
First Decision by Editorial Office Director |
|
2025-12-25 08:17 |
 |
Return for Revision |
|
2025-12-25 08:17 |
 |
Revised |
|
2026-01-05 07:16 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2026-02-13 02:34 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-02-13 03:24 |
 |
Articles in Press |
|
2026-02-13 03:24 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345